All you need to get started with ETF selection and analysis. Create your account now →
Help us improve your experience. Please confirm your investor type:
Compare ETFs Easily
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
PBPH ETF · Portfolio Building Block World Pharma and Biotech Index ETF
The PBPH Exchange Traded Fund (ETF) is provided by Tidal. It is built to track an index: BITA Global Pharma and Biotech Select Index. The PBPH ETF provides physical exposure, so by buying it you actually own parts of all the 52 underlying holdings. This share class generates a stream of income by distributing dividends.
Last update 4/24/2026, 1:30 PM UTC
LIVE
CLOSED
This fund is part ofDM Large & Mid Cap1M perf.+7.01%
Last price
$24.79
1M perf.
+1.68%
1M flows
+€31M
AuM
€627M
E/R
0.13%
Rating
Not rated
ESG Consensus®
PBPH
$24.79
Performance & flows
Segment for quartile rank
January 22, 2026 → April 22, 2026
Create a free account to view the flows graph
PBPH
$24.99
-3.77%
DM Large & Mid Cap
+4.37%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | +1.68%  | -3.77% | N/A | N/A | N/A | -1.35% | -1.35% | -0.77% | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
More details
NAV
4/22/2026
$25.02
1D NAV change
-0.31%
Dividend policy
Replication method
Direct (Physical)
Replication model
Full replication
No. of holdings
52
Inception date
11/24/2025
Jurisdiction
United States
Distribution
United States
Legal structure
Open-end Investment Company
Base currency
USD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Product type
Benchmark
BITA Global Pharma and Biotech Select Index
Asset class
Factors
N/A
Investment strategy
The Portfolio Building Block World Pharma and Biotech Index ETF seeks to track the performance, before fees and expenses, of the BITA Global Pharma and Biotech Select Index (the “Index”).
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
New to Trackinsight?
For individual investors
Essentials
A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.
More fund data
Compare up to 3 funds
More screener filters
Choose your own screener columns from 100+ metrics
Lists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring
For professional investors
Enterprise
Trackinsight Enterprise addresses the everyday operational, regulatory, and analytical pain points faced by professional and institutional ETF investors, from selection to execution.
Request a free trialSimilar ETFs in your region
IXJ
1M perf.
+0.44%
E/R
0.4%
IXJ
1M perf.
-0.69%
E/R
0.47%
XHC
1M perf.
+0.13%
E/R
0.66%
XDWH
1M perf.
+2.04%
E/R
0.25%
WHEA
1M perf.
+0.39%
E/R
0.3%
Advertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | -3.77% | N/A | N/A | N/A |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
More exposure metrics are available, exclusively in Trackinsight Enterprise
Exposure
Countries
USA
63.05%
Switzerland
10.48%
Japan
4.98%
United Kingdom
3.83%
Denmark
3.37%
France
2.68%
Germany
1.58%
Australia
1.39%
Unavailable
5.13%
Other
3.50%
Sectors
Health Care
85.65%
Unavailable
13.62%
Other
0.72%
Diversification
Total weight of top 15 holdings out of 52
Top 15 holdings
Data as of March 31, 2026
LILLY
JOHNSON&JOHNSON
ABBVIE
MERCK & CO INC
NOVARTIS
CH1499059983
GILEAD SCIENCES
AMGEN-T
Create a free account to view top holdings
PFIZER
BRISTOL-MYERS SQUIBB
DK0062498333
VERTEX PHARMACEUTICALS
SANOFI SA
GSK PLC
REGENERON PHARMACEUTICALS
Create a free account to view top holdings
More risk metrics are available, exclusively in Trackinsight Enterprise
Sustainability
Integrates ESG criteria
No
SDG
More sustainability metrics are available, exclusively in Trackinsight Enterprise
Replication
Trackinsight replication rating:
Not rated
1-year trailing difference
As of March 31, 2026
Create a free account to view the replication graph
PBPH
N/A
Replication quality
Calculated over 12m, as of March 31, 2026
Tracking error
Tracking difference
1-year cumulative return difference
Best
Worst
Daily return difference
Average
Worst
Replication information
Index
Index ticker
Index dividend policy
Replication method
Replication model
Issuer
Tidal
Tidal ID Card
Number of funds
12
Total AuM
€1.72B
Expense ratio range
0.13% - 1.99%
Average expense ratio
0.7475%
Top 5 funds by Tidal
Frequently asked questions about PBPH
What does Portfolio Building Block World Pharma and Biotech Index ETF, PBPH, invest in?
PBPH is a Passive ETF. This ETF provides exposure to Large Cap Developed markets Equities.
Which benchmark or index does PBPH replicate?
PBPH tracks the BITA Global Pharma and Biotech Select GRT Index - USD, through a full replication replication method.
What is the Total Expense ratio (TER) of PBPH?
PBPH carries a total expense ratio (TER) of 0.13%, indicating the annual cost for holding the fund.
When was PBPH launched?
PBPH was introduced to the market on November 24, 2025. It trades on United States
Who is the ETF issuer of PBPH?
Portfolio Building Block World Pharma and Biotech Index ETF, PBPH, is provided by Tidal. Learn more about Tidal here.
What is the current assets under management (AUM) of PBPH?
PBPH oversees €627M in assets as of April 22, 2026.
How has PBPH performed lately?
Based on data from April 22, 2026, PBPH returned 1.68% over the past month, -3.77% over the last three months and -0.77% year-to-date.
What are the latest inflows or outflows for PBPH?
As of April 22, 2026, PBPH recorded net flows of +€31M over the last month and +€665M year-to-date.
Does PBPH distribute dividends?
PBPH follows a distributing dividend policy, meaning it pays out income to investors.
What are the main country or region exposures of PBPH?
As of March 31, 2026, PBPH has significant geographic allocations in USA, Switzerland and Japan.
In which sector or theme does PBPH invest in?
As of March 31, 2026, PBPH focuses largely on Health Care.
How many securities does PBPH hold and how diversified is it?
As of March 31, 2026, PBPH holds 52 positions in its portfolio, with 71.34% of assets concentrated in its top 15 holdings.
What are the main positions in PBPH?
As of March 31, 2026, PBPH top three holdings include LILLY, JOHNSON&JOHNSON and ABBVIE.
What is the base currency of PBPH?
The base currency of PBPH is USD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
